{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T10:52:15Z","timestamp":1783075935198,"version":"3.54.6"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.parkreldis.2008.08.005","type":"journal-article","created":{"date-parts":[[2008,9,28]],"date-time":"2008-09-28T08:20:03Z","timestamp":1222590003000},"page":"351-353","source":"Crossref","is-referenced-by-count":40,"title":["Plasma amantadine concentrations in patients with Parkinson's disease"],"prefix":"10.1016","volume":"15","author":[{"given":"N.","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Moritoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2008.08.005_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","article-title":"Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease","volume":"41","author":"Deleu","year":"2002","journal-title":"Clin Pharm"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib2","series-title":"Martindale: the complete drug reference","first-page":"1129","article-title":"Amantadine hydrochloride","author":"Parfitt","year":"1999"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib3","series-title":"Goodman & Gilman's the pharmacological basis of therapeutics","first-page":"1209","article-title":"Antimicrobial agents: antiviral agents","author":"Hayden","year":"1996"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib4","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Verhagen Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib5","first-page":"19","article-title":"Amantadine hydrochloride pharmacokinetics in patients with impaired renal function","volume":"17","author":"Wu","year":"1982","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/clinchem\/26.2.295","article-title":"Gas-chromatographic determination of amantadine in human urine","volume":"26","author":"Stumph","year":"1980","journal-title":"Clin Chem"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"15","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib8","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/0003-9993(93)90072-I","article-title":"Amantadine-induced coma","volume":"74","author":"Macchio","year":"1993","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib9","first-page":"695","article-title":"Toxic effects of amantadine in patients with renal failure","volume":"120","author":"Ing","year":"1979","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib10","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1212\/WNL.56.2.279","article-title":"Amantadine-induced cortical myoclonus","volume":"56","author":"Matsunaga","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/mds.870110123","article-title":"Amantadine-induced \u201cvocal\u201d myoclonus","volume":"11","author":"Pfeiffer","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib12","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0922-4106(91)90113-V","article-title":"Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study","volume":"206","author":"Kornhuber","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1211\/0022357001774390","article-title":"N-Methyl-d-aspartate receptor antagonists enhance the head-twitch response, a 5-hydroxytryptamine2 receptor-mediated behaviour, in reserpine-treated mice","volume":"52","author":"Kim","year":"2000","journal-title":"J Pharm Pharmacol"},{"issue":"Suppl. 3","key":"10.1016\/j.parkreldis.2008.08.005_bib14","doi-asserted-by":"crossref","first-page":"iii53","DOI":"10.1007\/s00415-006-3010-x","article-title":"Pharmacokinetic characteristics of agents applied in the treatment of Parkinson's disease","volume":"253","author":"Nomoto","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00003088-198814010-00003","article-title":"Clinical pharmacokinetics of amantadine hydrochloride","volume":"14","author":"Aoki","year":"1988","journal-title":"Clin Pharm"},{"key":"10.1016\/j.parkreldis.2008.08.005_bib16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.7326\/0003-4819-94-4-454","article-title":"Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function","volume":"94","author":"Horadam","year":"1981","journal-title":"Ann Intern Med"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380200800240X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380200800240X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T17:30:08Z","timestamp":1588959008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135380200800240X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S135380200800240X"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2008.08.005","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}